Viralytics will use this report as a core source of data in the generation of its FDA Investigational New Drug (IND) filing. The Company has chosen to conduct its planned Phase II melanoma trial under an IND filing, as a clinical trial conducted under an IND filing adds significantly greater value in future licensing agreements than a trial undertaken below this regulatory standard.
VLA Price at posting:
$1.20 Sentiment: Hold Disclosure: Held
